Susan M. Lea

Susan M. Lea

Auto-generated profile, based on publicly available information

Susan M. Lea

University of Oxford, Sir William Dunn School of Pathology

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2004 in Acta Crystallographica Section D Structural Biology
Verified
Journal Article
Open access
PDF file
EBE. Blanc
E. Blanc
Pietro RoversiPietro Roversi
Pietro Roversi
CVC. Vonrhein
C. Vonrhein
CFC. Flensburg
C. Flensburg
SLS. M. Lea
S. M. Lea
GBG. Bricogne
G. Bricogne
BUSTER-TNT is a maximum-likelihood macromolecular refinement package. BUSTER assembles the structural model, scales observed and calculated structure-factor amplitudes and computes the model likelihood, whilst TNT handles the stereochemistry and NCS restraints/constraints and shifts the atomic coordinates, B factors and occupancies. In real space, in addition to the traditional atomic and bulk-solvent models, BUSTER models the parts of the structure for which an atomic model is not yet available ('missing structure') as low-resolution probability distributions for the random positions of the missing atoms. In reciprocal space, the BUSTER structure-factor distribution in the complex plane is a two-dimensional Gaussian centred around the structure factor calculated from the atomic, bulk-solvent and missing-structure models. The errors associated with these three structural components are added to compute the overall spread of the Gaussian. When the atomic model is very incomplete, modelling of the missing structure and the consistency of the BUSTER statistical model help structure building and completion because (i) the accuracy of the overall scale factors is increased, (ii) the bias affecting atomic model refinement is reduced by accounting for some of the scattering from the missing structure, (iii) the addition of a spatial definition to the source of incompleteness improves on traditional Luzzati and sigmaA-based error models and (iv) the program can perform selective density modification in the regions of unbuilt structure alone.

18 February 2009 in Nature
Verified
Journal Article
Open access
PDF file
MSMuriel C. Schneider
Muriel C. Schneider
BPBeverly E. Prosser
Beverly E. Prosser
JCJoseph J. E. Caesar
Joseph J. E. Caesar
EKElisabeth Kugelberg
Elisabeth Kugelberg
SLSu Li
Su Li
SLSusan M. Lea
Susan M. Lea
The human pathogen Neisseria meningitidis, a leading cause of bacterial meningitis and septic shock, possesses a surface protein, factor H binding protein or fHbp, that binds to host complement regulator factor H, thereby interfering with the immune response. Now the structure of the complex between human complement regulator factor H and fHbp has been determined. It reveals that the bacterial protein binds factor H by mimicking the glycosaminoglycans that occur naturally on host endothelial cells where they recruit factor H to prevent complement-mediated damage of the vascular tree. This work has important implications for the development of vaccines and therapeutics to counter meningococcal disease. Neisseria meningitidis possesses a surface protein called fHbp that binds to the complement regulator factor H, thereby interfering with the host immune response. Now the structure of N. meningitidis fHbp bound to factor H is presented, revealing the molecular interactions between these two molecules. The complement system is an essential component of the innate and acquired immune system1, and consists of a series of proteolytic cascades that are initiated by the presence of microorganisms. In health, activation of complement is precisely controlled through membrane-bound and soluble plasma-regulatory proteins including complement factor H (fH; ref. 2), a 155 kDa protein composed of 20 domains (termed complement control protein repeats). Many pathogens have evolved the ability to avoid immune-killing by recruiting host complement regulators3 and several pathogens have adapted to avoid complement-mediated killing by sequestering fH to their surface4. Here we present the structure of a complement regulator in complex with its pathogen surface-protein ligand. This reveals how the important human pathogen Neisseria meningitidis subverts immune responses by mimicking the host, using protein instead of charged-carbohydrate chemistry to recruit the host complement regulator, fH. The structure also indicates the molecular basis of the host-specificity of the interaction between fH and the meningococcus, and informs attempts to develop novel therapeutics and vaccines.

1 April 1993 in Nature
Verified
Journal Article
Closed access
DLDerek Logan
Derek Logan
RARobin Abu-Ghazaleh
Robin Abu-Ghazaleh
WBWendy Blakemore
Wendy Blakemore
SCStephen Curry
Stephen Curry
TJTerry Jackson
Terry Jackson
EFElizabeth Fry
Elizabeth Fry

4 March 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
EJElena Goicoechea de Jorge
Elena Goicoechea de Jorge
JCJoseph J. E. Caesar
Joseph J. E. Caesar
TMTalat H. Malik
Talat H. Malik
MPMitali Patel
Mitali Patel
MCMatthew Colledge
Matthew Colledge
SLSusan M. Lea
Susan M. Lea
The complement system is a key component regulation influences susceptibility to age-related macular degeneration, meningitis, and kidney disease. Variation includes genomic rearrangements within the complement factor H-related ( CFHR ) locus. Elucidating the mechanism underlying these associations has been hindered by the lack of understanding of the biological role of CFHR proteins. Here we present unique structural data demonstrating that three of the CFHR proteins contain a shared dimerization motif and that this hitherto unrecognized structural property enables formation of both homodimers and heterodimers. Dimerization confers avidity for tissue-bound complement fragments and enables these proteins to efficiently compete with the physiological complement inhibitor, complement factor H (CFH), for ligand binding. Our data demonstrate that these CFHR proteins function as competitive antagonists of CFH to modulate complement activation in vivo and explain why variation in the CFHRs predisposes to disease.

8 December 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
JPJoanne L. Parker
Joanne L. Parker
JDJustin C. Deme
Justin C. Deme
DKDimitrios Kolokouris
Dimitrios Kolokouris
GKGabriel Kuteyi
Gabriel Kuteyi
PBPhilip Biggin
Philip Biggin
SNSimon Newstead
Simon Newstead
Cysteine plays an essential role in cellular redox homoeostasis as a key constituent of the tripeptide glutathione (GSH). A rate limiting step in cellular GSH synthesis is the availability of cysteine. However, circulating cysteine exists in the blood as the oxidised di-peptide cystine, requiring specialised transport systems for its import into the cell. System xc− is a dedicated cystine transporter, importing cystine in exchange for intracellular glutamate. To counteract elevated levels of reactive oxygen species in cancerous cells system xc− is frequently upregulated, making it an attractive target for anticancer therapies. However, the molecular basis for ligand recognition remains elusive, hampering efforts to specifically target this transport system. Here we present the cryo-EM structure of system xc− in both the apo and glutamate bound states. Structural comparisons reveal an allosteric mechanism for ligand discrimination, supported by molecular dynamics and cell-based assays, establishing a mechanism for cystine transport in human cells.

1 February 1999 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
EFElizabeth Fry
Elizabeth Fry
SLSusan M. Lea
Susan M. Lea
TJTerry Jackson
Terry Jackson
JNJohn W.I. Newman
John W.I. Newman
FEFiona M. Ellard
Fiona M. Ellard
DSDavid Ian Stuart
David Ian Stuart
Heparan sulfate has an important role in cell entry by foot‐and‐mouth disease virus (FMDV). We find that subtype O1 FMDV binds this glycosaminoglycan with a high affinity by immobilizing a specific highly abundant motif of sulfated sugars. The binding site is a shallow depression on the virion surface, located at the junction of the three major capsid proteins, VP1, VP2 and VP3. Two pre‐formed sulfate‐binding sites control receptor specificity. Residue 56 of VP3, an arginine in this virus, is critical to this recognition, forming a key component of both sites. This residue is a histidine in field isolates of the virus, switching to an arginine in adaptation to tissue culture, forming the high affinity heparan sulfate‐binding site. We postulate that this site is a conserved feature of FMDVs, such that in the infected animal there is a biological advantage to low affinity, or more selective, interactions with glycosaminoglycan receptors.